Table 2.
Effect of sociodemographic properties on HRS, tumor size, stage and tumor grade
| Education level, n (%) | Economic Income (TL), n (%) | Place of Residence, n (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||
| None | Primary | Junior high | High school | Univesity | <500 | 500–1500 | >1500 | Urban | Rural | P* | ||
| Hormone receptor status | ER+ | 259 (67.6) | 202 (76.2) | 30 (63.8) | 49 (77.7) | 37 (80.4) | 123 (66.5) | 204 (67.5) | 250 (78.9) | 478 (73.5) | 99 (64.2) | <0.03 |
| ER− | 124 (32.4) | 63 (23.8) | 17 (36.2) | 14 (22.3) | 9 (19.6) | 62 (33.5) | 98 (32.5) | 67 (21.1) | 172 (26.5) | 55 (35.8) | ||
| PR+ | 258 (67.5) | 211 (80) | 32 (68) | 44 (71) | 35 (76) | 120 (64.8) | 220 (73) | 240 (76.2) | 479 (73.9) | 101 (66) | <0.04 | |
| PR− | 124 (32.5) | 53 (20) | 15 (32) | 18 (29) | 11 (24) | 65 (35.2) | 81 (27) | 75 (23.8) | 169 (26.1) | 52 (34) | ||
| HER2+ | 128 (33.3) | 87 (33) | 15 (31.9) | 22 (34.9) | 7 (15.2) | 65 (35.1) | 97 (31) | 97 (30.9) | 201 (31) | 58 (37.4) | >0.1 | |
| HER2− | 256 (66.7) | 176 (67) | 32 (68.1) | 41 (65.1) | 39 (84.8) | 120 (64.9) | 207 (69) | 217 (69.1) | 447 (69) | 97 (62.6) | ||
| Tumor size | <2 cm | 21 (5.5) | 29 (10.9) | 4 (8.7) | 13 (20.9) | 9 (19.6) | 9 (4.8) | 20 (6.6) | 47 (15) | 66 (10.2) | 10 (6.5) | <0.003a |
| 2–5 cm | 206 (54) | 147 (55.5) | 30 (65.2) | 36 (58.2) | 25 (54.3) | 81 (44.1) | 186 (61.2) | 177 (56.6) | 361 (55.9) | 83 (53.5) | ||
| >5 cm | 155 (40.5) | 89 (33.6) | 12 (26.1) | 13 (20.9) | 12 (26.1) | 94 (51.1) | 98 (32.2) | 89 (28.4) | 219 (33.9) | 62 (40) | ||
| Disease stage | 1 | 8 (2) | 13 (4.9) | 1 (2.1) | 6 (9.5) | 4 (8.7) | 2 (1.1) | 10 (3.2) | 20 (6.3) | 26 (4) | 6 (3.9) | <0.02 |
| 2 | 155 (39.9) | 120 (44.7) | 24 (50) | 32 (50.8) | 19 (41.3) | 56 (30.1) | 147 (47.6) | 147 (46.3) | 288 (44) | 62 (39.2) | ||
| 3 | 177 (45.6) | 120 (44.7) | 21 (43.8) | 22 (34.9) | 22 (47.8) | 112 (60.2) | 130 (42.1) | 120 (37.7) | 295 (45) | 67 (42.4) | ||
| 4 | 48 (12.5) | 15 (5.7) | 2 (4.1) | 3 (4.8) | 1 (2.2) | 16 (8.6) | 22 (7.1) | 31 (9.7) | 46 (7) | 23 (14.5) | ||
| Tumor grade | 1 | 17 (4.8) | 17 (6.8) | 4 (8.7) | 1 (1.6) | 4 (9.3) | 10 (5.7) | 17 (5.9) | 16 (5.6) | 39 (6.4) | 4 (2.8) | >0.2 |
| 2 | 174 (49.2) | 113 (45.4) | 22 (47.8) | 19 (31.7) | 21 (48.9) | 72 (41.1) | 130 (44.7) | 147 (51.4) | 279 (45.9) | 70 (48.6) | ||
| 3 | 163 (46) | 119 (47.8) | 20 (43.5) | 40 (66.7) | 18 (41.8) | 93 (53.2) | 144 (49.4) | 123 (43) | 290 (47.7) | 70 (48.6) | ||
a
There was no statistically significant correlation between place of residence and tumor size (p:0,1), n: Patient number
HRS: Hormone receptor status, ER: Estrogene receptor, PR: Progesteron receptor, HER2: Human epidermal growth factor receptor–2
*
Chi-square